Category: Medmonitor

83 posts found

FDA Declares Semaglutide Shortage Over

The GLP-1 receptor agonist has been considered in shortage since 2022, but the FDA confirmed with manufacturers that presented and projected demand can now be met.

Medmonitor

FDA Approves Novel Non-Opioid Journavx for Moderate to Severe Pain

A first-in-class medication, Journavx targets pain-signaling pathways involving sodium channels.

Medmonitor

FDA Approves Generic GLP-1 Victoza Injections for Type 2 Diabetes

Victoza® (liraglutide) injections are a GLP-1 receptor agonist, a drug class experiencing shortages due to their high demand.

Medmonitor

Generics Available for Lucemyra Tablets and Relistor Injection

These drugs treat opioid withdrawal and opioid-induced constipation, respectively.

Medmonitor

Imuldosa Approved as Stelara^® Biosimilar

This drug has been approved for the treatment of multiple chronic inflammatory disorders.

Medmonitor

FDA Considers Policy Changes for GLP-1 Compounds

Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.

Medmonitor

FDA Approves Zurnai and Neffy

Medmonitor

Recalls and Alerts Impacting Workers’ Comp

The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.

Medmonitor

Rezenopy Approved for Treatment of Opioid Overdose

A new naloxone nasal spray will soon be available.

Medmonitor

Lot of Methocarbamol Recalled Due to White Particles

Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.

Medmonitor

Cardiovascular Drug Approvals

As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.

Medmonitor

New Autoimmune Biosimilar Approved and Alzheimer’s Drug Goes Generic

Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.

Medmonitor

FDA Evaluates Report of Suicidal Thoughts with GLP-1 Receptor Agonist

While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.

Medmonitor

FDA Issues Respective Warnings for Compounded and Counterfeit Semaglutide

The growing demand for this drug has led individuals to search for semaglutide from alternative sources.

Medmonitor

FDA Warns of Rare Drug Interactions with Antiseizure Drugs

Hypersensitivity reactions may start as a rash but can quickly result in injury to internal organs.

1 2 3 4 5 6 Next